REG - ABCAM Plc - Director/PDMR Shareholding
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100319:nRSS9028Ia
RNS Number : 9028I
ABCAM Plc
19 March 2010
For immediate release 19 March 2010
19 March 2010
("Abcam" or "the Company")
Director's Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, announces that to meet demand from institutional investors the following transactions were undertaken by
Directors of the Company on 19 March 2010:
Director Number of 1 pence ordinary shares sold Price per share sold (p) Subsequent Beneficial Holding Percentage of issued share capital following sale
Jonathan Milner 400,000 1175 5,739,023 16.0%
Jim Warwick* 300,000 1175 580,052 1.6%
Jim Warwick*
300,000
1175
580,052
1.6%
*200,000 of these shares were sold by his wife, Jane Dominey.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Buchanan Communications
+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news